Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis.
Front Immunol
; 13: 923286, 2022.
Article
en En
| MEDLINE
| ID: mdl-36105796
ABSTRACT
Objectives:
A major challenge for COVID-19 therapy is dysregulated immune response associated with the disease. Umbilical cord mesenchymal stromal cells (UC-MSCs) may be a promising candidate for COVID-19 treatment owing to their immunomodulatory and anti-inflammatory functions. Therefore, this study aimed to evaluate the effectiveness of UC-MSCs inpatients with COVID-19.Method:
Medline, Embase, PubMed, Cochrane Library, and Web of Science databases were searched to collect clinical trials concerning UC-MSCs for the treatment of COVID-19. After literature screening, quality assessment, and data extraction, a systematic review and meta-analysis of the included study were performed.Results:
This systematic review and meta-analysis were prospectively registered on PROSPERO, and the registration number is CRD42022304061. After screening, 10 studies involving 293 patients with COVID-19 were eventually included. Our meta-analysis results showed that UC-MSCs can reduce mortality (relative risk [RR] =0.60, 95% confidence interval [CI] [0.38, 0.95], P=0.03) in COVID-19 patients. No significant correlation was observed between adverse events and UC-MSC treatment (RR=0.85, 95% CI [0.65, 1.10], P=0.22; RR=1.00, 95%CI [0.64, 1.58], P=1.00). In addition, treatment with UC-MSCs was found to suppress inflammation and improve pulmonary symptoms.Conclusions:
UC-MSCs hold promise as a safe and effective treatment for COVID-19. Systematic Review Registartion PROSPERO, identifier CRD42022304061.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Células Madre Mesenquimatosas
/
COVID-19
/
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Etiology_studies
/
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
Front Immunol
Año:
2022
Tipo del documento:
Article
País de afiliación:
China